Drugmakers agree to six-month DTC delay

Under fire over direct-to-consumer ads, which some Congressional legislators contend are misleading to consumers, pharmaceutical companies have agreed to voluntarily wait six months after drugs are approved before advertising to the public. The Congressmen pressuring the drug companies--Bart Stupak (D-MI) and John Dingell (D-MI)--aren't pleased, however, given that what they wanted was a two year DTC moratorium. Besides, even the drug companies themselves admit that they generally don't advertise within the first six months after product introductions anyway, given that they usually spend at least that much time educating doctors about drugs before beginning consumer advertising. Meanwhile, the pharmas turned down other requests, including that they only advertise products when studies have shown that they improve clinical outcomes (rather than having used biomarkers). (Looks like they gave up a whole lot of nothing, in other words.) The promise to delay on DTC advertising came as part of a hearing focused on ads for Pfizer's Lipitor, Johnson & Johnson's Procrit, and Merck/Schering-Plough's cholesterol drug Vytorin.

To learn more about the hearing:- read this Wall Street Journalblog item

The collection of patient-reported data at a health system is often highly fragmented and a burden to patients, staff and physicians alike. It can lead to inaccurate data, low completion rates, missed diagnoses, and high cost. This exciting webinar will discuss how to improve and optimize patient data collection to dramatically increase patient engagement. Reserve Your Spot Today!

FEATURED ADVISOR

Mina Ubbing is the president and CEO of Fairfield Medical Center, a 222-bed acute care hospital in Lancaster, Ohio. She is involved in marketing, wellness and strategic planning and is a chair of the board of trustees at the Ohio Hospital Association. She previously taught health administration at Ohio University Lancaster.